UNCY

UNCY

Unicycive Therapeutics, Inc.

5.15 USD

Last updated Sep 5, 10:56 UTC

Yesterday HIGH

$5.24

Yesterday LOW

$5.12

52w HIGH

$8.74

52w LOW

$3.72

EPS

-0.06

PE

-85.83

Next Earnings

Nov 11, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Unicycive Therapeutics, Inc. stock is up 1.98% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 5 September’s closed higher than August. In the last 3 Unusual Options Trades, there were 2 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

17 Jul 15:16	19 Feb, 2027	10.00	CALL	398	820
17 Jul 15:17	19 Feb, 2027	5.00	CALL	400	1464
24 Aug 17:30	16 Oct, 2026	5.00	PUT	500	0

Advanced Data Unlock

Benzinga Newsdesk

Tue Jun 30, 2026

Unicycive Therapeutics shares are trading lower after the company announced it received a Complete Response Letter from the FDA regarding the submitted New Drug Application for oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.
Webmaster

Tue Jun 30, 2026

Trading Halt: Halt status updated at 7:30:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Tue Jun 30, 2026

Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Letter Relates To Deficiencies Previously Identified At Third-Party Manufacturing Vendor

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has received a Complete Response Letter (CRL) from the
Webmaster

Tue Jun 30, 2026

Trading Halt: Halted at 7:00:00 a.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk

Fri Jun 5, 2026

Unicycive Therapeutics Files Base Prospectus For Offering Up To $150M Securities

https://www.sec.gov/Archives/edgar/data/1766140/000121390026065819/ea0291789-s3_unicycive.htm
Benzinga Newsdesk

Tue Jun 2, 2026

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $18

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $15 to $18.
Benzinga Newsdesk

Wed May 13, 2026

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $37

Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $40 to $37.
Benzinga Newsdesk

Tue May 12, 2026

Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 8 percent decrease over losses of $(0.50) per share
Benzinga Newsdesk

Mon Apr 6, 2026

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $15

Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and lowers the price target from $21 to $15.
Benzinga Newsdesk

Thu Apr 2, 2026

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $40

Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $46 to $40.

Benchmark

Thu Aug 20, 17:36

buy

confirm
Guggenheim

Thu Aug 13, 16:10

buy

confirm
B. Riley

Thu Aug 13, 15:54

buy

confirm

Advanced Data Unlock

DIA $532.33 USD

NTLA $12.75 USD

ETH ETH $23.42 USD

LLY $1,148.68 USD

NFLX $78.29 USD

ONON $27.99 USD